Affiliations: [a] Department of Neurology, Fundación Jiménez Díaz, Madrid, Spain | [b] Department of Neurology, Hospital Infanta Elena, Madrid, Spain | [c] Department of Neurology, Hospital Severo Ochoa, Madrid, Spain | [d] Department of Neurology, Hospital Virgen del Rocío, Seville, Spain | [e] Department of Genetics, Fundación Jiménez Díaz, Madrid, Spain | [f] Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD) and CIBERER, Madrid, Spain | [g] Secugen S.L., Madrid, Spain
Correspondence:
[*]
Correspondence to: Dr. Estrella Gómez-Tortosa, MD, PhD, Department of Neurology, Fundación Jiménez Díaz, 28040 Madrid, Spain. Tel.: +34 91 5504800/Ext. 2063; E-mail: egomezt@fjd.es.
Abstract: For diagnostic purposes, we screened for the C9ORF72 mutation in a) 162 FTLD cases, and b) 145 cases with other diagnoses but with some frontotemporal features or manifestations previously reported in C9 carriers. Ten cases (onset 50 to 75 years) harbored the expansion: seven had FTLD syndromes (4.3% of total, 11% of familial cases), and three (2%) had a different diagnosis. All positive cases had family history of dementia, psychiatric disease, or ALS, but only 20% of families with mixed FTLD/ALS phenotypes carried the expansion. Language impairment was the most common symptom, followed by behavioral changes, memory deficits, and parkinsonism. C9ORF72 mutation has a low frequency in our dementia series and very diverse clinical manifestations.
